Dengue Fever – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Dengue Fever – Pipeline Review, H2 2016’, provides an overview of the Dengue Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Dengue Fever

The report reviews pipeline therapeutics for Dengue Fever by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Dengue Fever therapeutics and enlists all their major and minor projects

The report assesses Dengue Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Dengue Fever

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Dengue Fever

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abivax SA

Agilvax Inc

Altravax Inc

Biological Mimetics Inc

Bioneer Corp

Biotron Ltd

Codagenix Inc

Emergent BioSolutions Inc

Ennaid Therapeutics LLC

GeneSegues Inc

GlaxoSmithKline Plc

Globavir Biosciences Inc

Hawaii Biotech Inc

HSRx Group

Humabs BioMed SA

Immunotope Inc

Inovio Pharmaceuticals Inc

Johnson & Johnson

Kineta Inc

Merck & Co Inc

Molplex Ltd

NanoViricides Inc

Novartis AG

NovaTarg Therapeutics Inc

Panacea Biotec Ltd

Plex Pharmaceuticals Inc

ProtInhi BV

Regeneron Pharmaceuticals Inc

Sarepta Therapeutics Inc

SIGA Technologies Inc

Sun Pharma Advanced Research Company Ltd

Takeda Pharmaceutical Company Ltd

TechnoVax Inc

Themis Bioscience GmbH

VaxInnate Corp

Visterra Inc

VLP Therapeutics LLC

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Dengue Fever Overview 6

Therapeutics Development 7

Dengue Fever - Therapeutics under Development by Companies 9

Dengue Fever - Therapeutics under Investigation by Universities/Institutes 12

Dengue Fever - Pipeline Products Glance 14

Dengue Fever - Products under Development by Companies 17

Dengue Fever - Products under Investigation by Universities/Institutes 20

Dengue Fever - Companies Involved in Therapeutics Development 22

Dengue Fever - Therapeutics Assessment 59

Drug Profiles 68

Dengue Fever - Dormant Projects 164

Dengue Fever - Discontinued Products 170

Dengue Fever - Product Development Milestones 171

Appendix 184

List of Tables

List of Tables

Number of Products under Development for Dengue Fever, H2 2016 17

Number of Products under Development for Dengue Fever – Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Development by Companies, H2 2016 (Contd..1) 20

Number of Products under Development by Companies, H2 2016 (Contd..2) 21

Number of Products under Investigation by Universities/Institutes, H2 2016 23

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Development, H2 2016 26

Products under Development by Companies, H2 2016 27

Products under Development by Companies, H2 2016 (Contd..1) 28

Products under Development by Companies, H2 2016 (Contd..2) 29

Products under Investigation by Universities/Institutes, H2 2016 30

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 31

Dengue Fever – Pipeline by Abivax SA, H2 2016 32

Dengue Fever – Pipeline by Agilvax Inc, H2 2016 33

Dengue Fever – Pipeline by Altravax Inc, H2 2016 34

Dengue Fever – Pipeline by Biological Mimetics Inc, H2 2016 35

Dengue Fever – Pipeline by Bioneer Corp, H2 2016 36

Dengue Fever – Pipeline by Biotron Ltd, H2 2016 37

Dengue Fever – Pipeline by Codagenix Inc, H2 2016 38

Dengue Fever – Pipeline by Emergent BioSolutions Inc, H2 2016 39

Dengue Fever – Pipeline by Ennaid Therapeutics LLC, H2 2016 40

Dengue Fever – Pipeline by GeneSegues Inc, H2 2016 41

Dengue Fever – Pipeline by GlaxoSmithKline Plc, H2 2016 42

Dengue Fever – Pipeline by Globavir Biosciences Inc, H2 2016 43

Dengue Fever – Pipeline by Hawaii Biotech Inc, H2 2016 44

Dengue Fever – Pipeline by HSRx Group, H2 2016 45

Dengue Fever – Pipeline by Humabs BioMed SA, H2 2016 46

Dengue Fever – Pipeline by Immunotope Inc, H2 2016 47

Dengue Fever – Pipeline by Inovio Pharmaceuticals Inc, H2 2016 48

Dengue Fever – Pipeline by Johnson & Johnson, H2 2016 49

Dengue Fever – Pipeline by Kineta Inc, H2 2016 50

Dengue Fever – Pipeline by Merck & Co Inc, H2 2016 51

Dengue Fever – Pipeline by Molplex Ltd, H2 2016 52

Dengue Fever – Pipeline by NanoViricides Inc, H2 2016 53

Dengue Fever – Pipeline by Novartis AG, H2 2016 54

Dengue Fever – Pipeline by NovaTarg Therapeutics Inc, H2 2016 55

Dengue Fever – Pipeline by Panacea Biotec Ltd, H2 2016 56

Dengue Fever – Pipeline by Plex Pharmaceuticals Inc, H2 2016 57

Dengue Fever – Pipeline by ProtInhi BV, H2 2016 58

Dengue Fever – Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 59

Dengue Fever – Pipeline by Sarepta Therapeutics Inc, H2 2016 60

Dengue Fever – Pipeline by SIGA Technologies Inc, H2 2016 61

Dengue Fever – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 62

Dengue Fever – Pipeline by Takeda Pharmaceutical Company Ltd, H2 2016 63

Dengue Fever – Pipeline by TechnoVax Inc, H2 2016 64

Dengue Fever – Pipeline by Themis Bioscience GmbH, H2 2016 65

Dengue Fever – Pipeline by VaxInnate Corp, H2 2016 66

Dengue Fever – Pipeline by Visterra Inc, H2 2016 67

Dengue Fever – Pipeline by VLP Therapeutics LLC, H2 2016 68

Assessment by Monotherapy Products, H2 2016 69

Number of Products by Stage and Target, H2 2016 71

Number of Products by Stage and Mechanism of Action, H2 2016 73

Number of Products by Stage and Route of Administration, H2 2016 75

Number of Products by Stage and Molecule Type, H2 2016 77

Dengue Fever – Dormant Projects, H2 2016 174

Dengue Fever – Dormant Projects (Contd..1), H2 2016 175

Dengue Fever – Dormant Projects (Contd..2), H2 2016 176

Dengue Fever – Dormant Projects (Contd..3), H2 2016 177

Dengue Fever – Dormant Projects (Contd..4), H2 2016 178

Dengue Fever – Dormant Projects (Contd..5), H2 2016 179

Dengue Fever – Discontinued Products, H2 2016 180

List of Figures

List of Figures

Number of Products under Development for Dengue Fever, H2 2016 17

Number of Products under Development for Dengue Fever – Comparative Analysis, H2 2016 18

Number of Products under Development by Companies, H2 2016 19

Number of Products under Investigation by Universities/Institutes, H2 2016 22

Comparative Analysis by Late Stage Development, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 25

Comparative Analysis by Early Stage Products, H2 2016 26

Assessment by Monotherapy Products, H2 2016 69

Number of Products by Top 10 Targets, H2 2016 70

Number of Products by Stage and Top 10 Targets, H2 2016 70

Number of Products by Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 72

Number of Products by Routes of Administration, H2 2016 74

Number of Products by Stage and Routes of Administration, H2 2016 74

Number of Products by Top 10 Molecule Types, H2 2016 76

Number of Products by Stage and Top 10 Molecule Types, H2 2016 76

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports